monoclonal antibody AMG 145
Jump to navigation
Jump to search
Indications
- dyslipidemia, with increased LDL cholesterol
- may be used with statin
Mechanism of action
- inhibits PCSK9
- decreases LDL cholesterol (50%)
More general terms
References
- ↑ Giugliano RP et al Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study The Lancet, Early Online Publication, 6 November 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23141813 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61770-X/abstract
Koren MJ et al Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study The Lancet, Early Online Publication, 6 November 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23141812 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61771-1/abstract
Tonkin AM and Watts GF Into the future: diversifying lipid management The Lancet, Early Online Publication, 6 November 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23141810 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61888-1/fulltext - ↑ Raal F et al Low-Density Lipoprotein Cholesterol-Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) Randomized Trial. Circulation. 2012 Nov 5. [Epub ahead of print] PMID: https://www.ncbi.nlm.nih.gov/pubmed/23129602
- ↑ Sullivan D et al Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial. JAMA. 2012 Nov 5:1-10 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23128163